Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate), a prodrug of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole L-lysine ethanolate can be used for candidiasis, onychomycosis and parasitemia research.

GSK778 (iBET-BD1) is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC50s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively. GSK778 phenocopies the effects of pan-BET inhibitors in cancer models.

CU115 is a potent TLR8 antagonist (IC50=1.04 µM), and shows selective for TLR8 over TLR7 (IC50=>50 µM). CU 115 decreases TNF-α and IL-1β production activated by R-848 in THP-1 cells.

MBCQ is a potent and selective the type V phosphodiesterase (PDE V; PDE5) inhibitor with an IC50 of 19 nM. MBCQ has IC50s >100 µM for PDE1, PDE2, PDE3, and PDE4, respectively. MBCQ dilates coronary arteries via potent and specific inhibition of cGMP-PDE.

YM-750 is a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor (IC50=0.18 μM). ACAT catalyzes the formation of cholesteryl esters from cholesterol and long-chain fatty-acyl-coenzyme A.

NSC-105808 is a potent, specific DNA2 nuclease inhibitor with IC50s of 2.0 and 1.49 μM for yeast DNA2 and human DNA2. NSC-105808 inhibits homologous recombination (HR) repair, double-strand DNA breaks (DSB) end resection and suppresses proliferation of cancer cells.

4-APC hydrobromide is a highly sensitive and selective derivatization agent for aldehydes. 4-APC hydrobromide possesses an aniline moiety for a fast selective reaction with aliphatic aldehydes as well as a quaternary ammonium group for improved MS sensitivity. 4-APC hydrobromide allows highly sensitive and selective MS detection of aldehydes.

ALC-0315 is an ionisable aminolipid that used for mRNA compaction and aids mRNA cellular delivery. ALC-0315 can be used to form lipid nanoparticle (LNP) delivery vehicles.

Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib hydrochloride can be used for the research of relapsed or refractory B-cell malignancies.

Glutaminase-IN-3 (compound 657) is a potent glutaminase inhibitor extracted from patent WO2014089048A1, compound 657, has an IC50 of 0.24 μM for Glutaminase 1 (GLS1).

Novel lipid-lowering agent, acting as an AMPK activator, increasing ABCA1 protein expression and improving hepatic lipid metabolism and leukocyte trafficking in experimental hepatic steatosis

Novel SIRT6 activator, significantly inhibiting the proliferation and migration of pancreatic ductal adenocarcinoma (PDAC) cells in vitro and markedly suppressing the tumor growth in a PDAC tumor xenograft model

ARN-21934 is a novel potent and highly selective inhibitor for human topoisomerase II α over β.

Novel potent and selective NADPH oxidase inhibitor, targeting Nox4 in TGFβ-induced lens epithelial to mesenchymal transition

Novel mucolipin 1 (ML1) agonist, inducing lysosomal Ca2+ release, ameliorating muscular dystrophies and activating TFEB to correct lysosomal insufficiency in mdx mice

Hydrophobic inducer of the degradation of stabilized proteins, degrading HaloTag2 fusion proteins

SSAA09E2 is a novel inhibitor of SARS-CoV replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2)

Novel potent inhibitor of the GRK2--​dependent bovine tubulin oxidation

B3C is an activator of transcription factor MEF2D; Enhabcer of cognitive capacity; Blocker of N-methyl-D-aspartate receptors.

Novel inhibitor of SARS-CoV replication, acting by preventing fusion of the viral membrane with the host cellular membrane

Novel VISTA (V-domain immunoglobulin suppressor of T-cell activation) agonist

Novel covalent antagonist of hsSTING